Are Peptides Legal Under the 2026 HHS Peptide Policy?

The October 2026 Department of Health and Human Services (HHS) draft policy covers six peptides under limited enforcement discretion: BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. The policy applies only when every listed condition is met, including a patient-specific prescription and a single active ingredient. It does not approve these peptides or add them to the 503A bulks list. The draft is open for comment for two weeks after its October 30, 2026 Federal Register publication.^1,2

The Scope of the HHS Peptide Policy

Enforcement discretion means HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician when the draft policy’s conditions are met.¹ It is a statement about enforcement priorities. It does not change the approval status of any peptide.

HHS describes the policy as an interim way to expand patient access while the Food and Drug Administration (FDA) reviews the six bulk drug substances.¹ FDA may later propose adding some or all of them to the 503A bulks list through rulemaking.²

The draft has several limits:

• It does not add any peptide to the 503A bulks list.
• It does not establish that any peptide is safe or effective.
• It does not set a dose or treatment schedule.
• It does not cover blends or research-use-only products.
• It does not name 503B outsourcing facilities.
• It is not binding on HHS or the public.^1,2

The Federal Register notice was filed for public inspection on October 28, 2026, with publication scheduled for October 30, 2026. Written comments may be submitted through Docket HHS-OASH-2026-0496 for two weeks after publication.²

Your practical path depends on the product, route, prescriber, pharmacy, and prescription. The peptide name alone does not tell you whether the draft policy applies.

A headline about enforcement discretion cannot tell you whether a peptide belongs in your care. That answer comes from a physician who has read your labs before any treatment is offered.

The Six Peptides and Their Listed Routes

The table below is compiled from HHS’s Appendix B, FDA’s July 2026 advisory-committee meeting record, and FDA’s compounding safety-risk page. It shows the exact form and route identified by HHS, the use reviewed by the FDA advisory committee, and FDA’s published human-data finding.^1,3,4

An advisory-committee review does not establish clinical benefit. The FDA findings in the final column describe gaps in available human safety or exposure data. They do not show that a listed product is safe or effective.^3,4

Your physician must therefore evaluate more than whether a peptide appears in Appendix A. The proposed route, product composition, pharmacy, medical history, medications, symptoms, and treatment goal all affect whether a prescription is appropriate.

The Ten Conditions for Enforcement Discretion

All ten HHS conditions must be present for a compounded product to fall within the draft policy.¹ A product does not fit the policy simply because its label names one of the six peptides.

1. The bulk drug substance appears in Appendix A.
2. Its identity and route match the limits in Appendix B.
3. The substance comes from a facility registered under section 510, with a valid certificate of analysis covering identity, purity, potency, and listed contaminants.
4. The original manufacturer is FDA-registered and compliant with current good manufacturing practice. Its name and location appear on the certificate of analysis.
5. The compounder reports compounded products, serious adverse events, and product-quality issues to FDA MedWatch and the relevant states. The patient label explains the reporting procedure.
6. The label states, “This is a compounded drug product. Not for resale.”
7. The product contains one active pharmaceutical ingredient from Appendix A.
8. An oral product has documentation showing that its specific formulation achieves adequate oral bioavailability in humans.
9. Any co-packaged drug-delivery device is an FDA 510(k)-cleared syringe.
10. The product satisfies the other applicable Federal Food, Drug, and Cosmetic Act requirements, including the patient-specific prescription requirement under section 503A.

These conditions make the prescription and dispensing process part of the policy. If you are considering a covered peptide, your physician and dispensing pharmacy need to determine whether the specific product fits every condition.

The Path From Category 2 to the Draft Policy

All six peptides were in FDA Category 2 from September 29, 2023, until April 22, 2026.¹ FDA lists them as nominated bulk drug substances that their nominators later withdrew.³ HHS Appendix B states that neither their placement in Category 2 nor their removal changed their status under section 503A.¹

The FDA Pharmacy Compounding Advisory Committee reviewed the substances on July 23 and 24, 2026.⁴ HHS Appendix B records that the Center for Drug Evaluation and Research recommended against listing each of the six substances, while the advisory committee voted in favor.¹

McDermott Will & Schulte reported these committee votes in favor:⁵

• BPC-157: 8 to 6, one abstention
• KPV: 8 to 6, one abstention
• TB-500: 8 to 6, one abstention
• MOTS-c: 7 to 5, two abstentions
• Epitalon: 7 to 4, one abstention
• Semax: 8 to 5, one abstention

Those votes were advisory. The committee did not approve the substances or change federal law. The HHS draft policy came later and created the limited enforcement position that now applies while FDA continues its review.^1,2

Where Research-Use, Blended, and Unlisted Peptides Stand

Research-use-only products and products sold by online sellers fall outside the HHS draft policy.¹ The policy specifically states that it aims to discourage widespread use of certain research-use-only peptides supplied by foreign manufacturers that may present safety risks to patients in the United States.

Products combining BPC-157 with TB-500, sometimes called a Wolverine Stack, fall outside the policy because Appendix A products must contain only one listed active pharmaceutical ingredient.¹ The same limit applies to a blend of BPC-157 and KPV.

The single-ingredient condition leaves no room for a standard blend. The treatment decision still belongs with a physician who has reviewed your labs, existing conditions, and current medications.

Selank acetate appears on FDA’s withdrawn-nomination list, but it does not appear in HHS Appendix A.³ The policy therefore does not cover Selank. A comparison of Semax and Selank can help you separate the two compounds and avoid treating one policy entry as though it applies to both.

Emideltide, also called DSIP, was reviewed for opioid withdrawal, chronic insomnia, and narcolepsy. McDermott Will & Schulte reported that the committee did not recommend it, with six yes votes, seven no votes, and one abstention.^4,5 It does not appear in Appendix A.

Every other unlisted peptide also falls outside this draft policy. HHS may revisit the interim policy if a safety signal or product-quality issue arises.¹

Physician-Led Access Under the Policy

A covered product begins with a licensed physician and a patient-specific prescription.¹ You cannot determine whether the policy applies by looking only at a peptide vial, website, or product name.

A physician first needs to decide whether peptide therapy fits your symptoms, goals, medical history, medications, and laboratory findings. If treatment is appropriate, the prescription must identify a form and route covered by Appendix B. A state-licensed 503A pharmacy must then compound the single-ingredient product under the remaining conditions.

Starting with a peptide to address one symptom can mask the cause when there has been no workup. Labs give your physician the information needed to make the prescription decision around your health.

The sourcing questions are separate from the treatment decision. Our guide to peptide sourcing and pharmacy checks explains how to review the dispensing source and certificate of analysis without turning the process into a do-it-yourself verification exercise.

Labs provide a baseline and help your physician assess the wider pattern behind the symptom you want to address. Fatigue, poor recovery, sleep changes, and body-composition concerns can involve hormones, metabolic markers, inflammation, nutrition, or sleep. One symptom rarely identifies one cause.

The Opt Take on Peptide Legality

At Opt Health, a physician decides whether a listed peptide belongs in your plan at all after reading your 55+ biomarker panel. The policy’s patient-specific prescription requirement matches how treatment decisions already work here.

Your initial panel can be completed at home or through a partner lab, and a physician then reviews the results with you in a 1:1 consultation. Existing conditions and current medications are part of that initial review. The policy determines whether enforcement discretion may apply to a specific compounded product. Your physician determines whether any treatment belongs in your plan.

Membership is required to receive treatment because continuity of care is part of the process. A full blood panel and physician consultation repeat every three to four months, allowing the plan to be assessed against your updated numbers. The care team is also available through chat seven days a week.

You can learn more about physician-guided peptide therapy before discussing your options. If you are asking whether peptides are legal, start by identifying the exact substance, route, prescription, and dispensing pharmacy covered by your physician’s plan.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.